Refractory Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
2 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| cyt-0851 | Cyteir Therapeutics, Inc. (CYT) |
Phase 1(1)
| Drug | Company |
|---|---|
| tti-622 | Trillium Therapeutics Inc. (TRIL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Refractory Lymphoma?
BioSniper tracks 2 drugs in development for Refractory Lymphoma across 2 companies.
How many clinical trials target Refractory Lymphoma?
There are 3 clinical trials targeting Refractory Lymphoma tracked by BioSniper.
What is the prevalence of Refractory Lymphoma?
The estimated prevalence of Refractory Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Refractory Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis